On January 26th, 2023, our NEPHSTROM partner Orbsen Therapeutics Limited, a global leader in stromal cell immunotherapies, announced encouraging headline interim results from the EU Horizon 2020-funded clinical trial for Diabetic Kidney Disease. NEPHSTROM is a randomized, double-blind, placebo-controlled Phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell immunotherapy, ORBCEL™, in adult study subjects with type 2 diabetes and progressive diabetic kidney disease (DKD). ORBCEL is a proprietary formulation of highly purified immunomodulatory stromal cells. This investigator-sponsored, multi-centre study was led by the Mario Negri Institute for Pharmacological Research IRCCS (Bergamo, Italy).
Read the entire press release here.
NEPHSTROM has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634086.